Evidence map›Paper›PMID 25553280›Full record

ArticleAnnals of laboratory medicine2015

Highly sensitive and novel point-of-care system, aQcare Chlamydia TRF kit for detecting Chlamydia trachomatis by using europium (Eu) (III) chelated nanoparticles.

Ji Yeon Ham, Jaean Jung, Byung-Gap Hwang, Won-Jung Kim, Young-Seop Kim, Eun-Ju Kim, Mi-Yeon Cho, Mi-Sun Hwang, Dong Il Won, Jang Soo Suh

Abstract readEvaluation Study
In one paragraph

Article in Annals of laboratory medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Progress and Perspectives in Point of Care Testing for Urogenital Chlamydia trachomatis Infection: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ji Yeon HamDepartment of Laboratory Medicine, Kyungpook National University Hospital, Daegu, Korea.
Jaean JungMedisensor Inc., Daegu, Korea.
Byung-Gap HwangMedisensor Inc., Daegu, Korea.
Won-Jung KimMedisensor Inc., Daegu, Korea.
Young-Seop KimMedisensor Inc., Daegu, Korea.
Eun-Ju KimMedisensor Inc., Daegu, Korea.
Mi-Yeon ChoMedisensor Inc., Daegu, Korea.
Mi-Sun HwangMedisensor Inc., Daegu, Korea.
Dong Il WonDepartment of Laboratory Medicine, Kyungpook National University Hospital, Daegu, Korea. ; Department of Clinical Pathology, Kyungpook National University School of Medicine, Daegu, Korea.
Jang Soo SuhDepartment of Laboratory Medicine, Kyungpook National University Hospital, Daegu, Korea. ; Department of Clinical Pathology, Kyungpook National University School of Medicine, Daegu, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe bacterium Chlamydia trachomatis is one of the leading causes of sexually transmitted diseases worldwide. Since no simple and effective tool exists to diagnose C. trachomatis infections, we evaluated a novel point-of-care (POC) test, aQcare Chlamydia TRF kit, which uses europium-chelated nanoparticles and a time-resolved fluorescence reader.

methodsThe test performance was evaluated by comparing the results obtained using the novel POC testing kit with those obtained using a nucleic acid amplification test (NAAT), using 114 NAAT-positive and 327 NAAT-negative samples.

resultsThe cut-off value of the novel test was 20.8 with a detection limit of 0.27 ng/mL. No interference or cross-reactivity was observed. Diagnostic accuracy showed an overall sensitivity of 93.0% (106/114), specificity of 96.3% (315/327), positive predictive value (PPV) of 89.8% (106/118), and negative predictive value (NPV) of 97.5% (315/323). The sensitivity of the novel test was much higher than that of currently available POC tests. Furthermore, the relative ease and short turnaround time (30 min) of this assay enables C. trachomatis-infected individuals to be treated without a diagnostic delay.

conclusionsThis simple and novel test is a potential tool to screen a larger population, especially those in areas with limited resources.

Indexed as

AdultAgedAged, 80 and overChlamydia InfectionsChlamydia trachomatisDNA, BacterialEuropiumFemaleHumansMaleMetal NanoparticlesMiddle AgedPoint-of-Care SystemsReagent Kits, DiagnosticReal-Time Polymerase Chain ReactionSensitivity and SpecificityDNA, BacterialEuropiumReagent Kits, DiagnosticChlamydia trachomatisEuropiumPoint-of-care systems

Identifiers

PMID25553280
PMCPMC4272965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.